◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › GERN

Geron Corporation (GERN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Geron Corporation (GERN) operates in the Biotechnology industry and is headquartered in Foster City, United States with about 258 employees. Its market capitalization is roughly $998 million. In the fiscal year ended 2025-12-31, GERN reported $184M in revenue and ($84M) in net income.

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

Interactive charts & full statements → Open the GERN valuation workbench →

GERN Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$184M$77M$0M$1M
Gross Profit$179M$76M$0M$1M
Operating Income (EBIT)($52M)($174M)($194M)($139M)
Net Income($84M)($175M)($184M)($142M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GERN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$52M$48M$47M$49M$40M
Gross Profit$50M$47M$46M$48M$38M
Operating Income (EBIT)($0M)($8M)($14M)($12M)($17M)
Net Income($4M)($29M)($18M)($16M)($20M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GERN Free Cash Flow History

GERN Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$570M$594M$394M$191M
Total Liabilities$345M$314M$146M$111M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GERN viewer.

Other Companies in Biotechnology

← GEOSAll stocksGETY →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.